ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2895

Bacterial Amyloids Promote Type I Interferon Production and Accelerate Autoimmunity

Paul Gallo, Glenn Rapsinski, Cagla Tukel and Stefania Gallucci, Dept. of Microbiology and Immunology, Laboratory of Dendritic Cell Biology, Temple Autoimmunity Center, Temple University School of Medicine, Philadelphia, PA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Bacterial infections, Dendritic cells, interferons and mouse model, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Infection is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE).  This is largely due to the use of potent immunosuppressive therapy, but may also stem from inherent immune dysregulation.  Curli is a bacterial amyloid that serves as a component of enteric bacterial biofilms including those of Escherichia coli and Salmonella enterica serovar Typhimurium.  Patients are exposed to curli during urinary tract infections, gastrointestinal infections, and sepsis.  Nucleic acids are also an integral part of curli biofilms as treatment with DNases leads to biofilm dissociation.  Here we studied the immune response to nucleic acid-containing curli amyloids in the context of murine SLE.

Methods: Curli amyloid was isolated from Salmonella bacterial cultures.  In vitro studies were performed using bone marrow-derived dendritic cells (BMDCs) from wild type and lupus-prone mice.  BMDCs were activated with a dose titration of curli amyloid.  Synthetic curli was used to study the role of nucleic acids in the immune response.  In vivo studies were performed using lupus-prone NZBW-F1 mice.  To simulate a chronic bacterial infection, eight 6-week-old mice were injected intraperitoneally (i.p.) with curli or PBS three times a week for 5 weeks and monitored for autoantibody production.

Results: We found that curli amyloids from bacterial cultures contain abundant nucleic acids and that exogenous DNA enhances amyloid fibrillization.  BMDCs strongly respond to curli, producing large quantities of IL-12, IL-6, and IL-10.  Curli also induces expression of IFN-β and IFN-simulated genes, with BMDCs from lupus-prone mice over-expressing these genes compared to wild type.  Using both natural and synthetic curli, we found that curli and nucleic acids synergize to activate DCs.  Lupus-prone NZBW-F1 mice injected i.p. with curli, compared to PBS, produce high quantities of anti-dsDNA and anti-chromatin autoantibodies within 2 weeks of the first injection.

Conclusion: The bacterial amyloid curli contains nucleic acids which are integral to the immune response to bacterial biofilms.  Curli is a potent activator of dendritic cells and can rapidly accelerate autoimmunity in lupus-prone mice.  This work suggests that nucleic acid-containing bacterial amyloids are an important environmental trigger for lupus and that curli injection may be useful as a novel method to accelerate murine lupus.


Disclosure:

P. Gallo,
None;

G. Rapsinski,
None;

C. Tukel,
None;

S. Gallucci,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bacterial-amyloids-promote-type-i-interferon-production-and-accelerate-autoimmunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology